{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:28:09Z","timestamp":1788672489488,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016819","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00775-5","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:39:25Z","timestamp":1751683165000},"page":"855-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02728752","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Schessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bata-Cs\u00f6rg\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-989X","authenticated-orcid":false,"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-7911","authenticated-orcid":false,"given":"Zoltan","family":"Griger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7232-4640","authenticated-orcid":false,"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-3111","authenticated-orcid":false,"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-5292","authenticated-orcid":false,"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-0713","authenticated-orcid":false,"given":"Jiri","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ProDERM investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"issue":"11","key":"775_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY, Leclair V, Lamb JA, Chinoy H. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2023;19(11):695\u2013712.","journal-title":"Nat Rev Rheumatol"},{"key":"775_CR2","unstructured":"Orphanet. Dermatomyositis. Last updated February 2021. https:\/\/www.orpha.net\/en\/disease\/detail\/221. Accessed Apr 2025."},{"issue":"2","key":"775_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acr.24786","volume":"75","author":"VL Kronzer","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM 3rd, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res. 2023;75(2):348\u201355.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"775_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40674-022-00193-6","volume":"8","author":"MP Chung","year":"2022","unstructured":"Chung MP, Paik JJ. Past, present, and future in dermatomyositis therapeutics. Curr Treatm Opt Rheumatol. 2022;8(4):71\u201390.","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"8","key":"775_CR5","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e55","volume":"34","author":"SK Cho","year":"2019","unstructured":"Cho SK, Kim H, Myung J, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a nationwide population-based study. J Korean Med Sci. 2019;34(8):e55.","journal-title":"J Korean Med Sci"},{"key":"775_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","volume":"4","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus. 2015;4:240.","journal-title":"Springerplus"},{"issue":"6","key":"775_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614\u201322.","journal-title":"Arthritis Rheum"},{"key":"775_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fmed.2019.00326","volume":"6","author":"B Hervier","year":"2019","unstructured":"Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment. Front Med. 2019;6:326.","journal-title":"Front Med"},{"issue":"4","key":"775_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/s-2007-985666","volume":"28","author":"M Fathi","year":"2007","unstructured":"Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007;28(4):451\u20138.","journal-title":"Semin Respir Crit Care Med"},{"key":"775_CR10","doi-asserted-by":"publisher","unstructured":"Joint involvement. In: Dermatomyositis. Berlin: Springer. https:\/\/doi.org\/10.1007\/978-3-540-79313-7_9. Accessed Apr 2025.","DOI":"10.1007\/978-3-540-79313-7_9"},{"issue":"11","key":"775_CR11","first-page":"1424","volume":"26","author":"L Christopher-Stine","year":"2020","unstructured":"Christopher-Stine L, Wan GJ, Kelly W, McGowan M, Bostic R, Reed ML. Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J Manag Care Spec Pharm. 2020;26(11):1424\u201333.","journal-title":"J Manag Care Spec Pharm"},{"key":"775_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.55563\/clinexprheumatol\/p8x98o","volume":"40","author":"G Ricci","year":"2022","unstructured":"Ricci G, Fontanelli L, Torri F, Schirinzi E, Siciliano G. Fatigue as a common signature of inflammatory myopathies: clinical aspects and care. Clin Exp Rheumatol. 2022;40:425\u201332.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"775_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/diagnostics12051200","volume":"12","author":"A Matas-Garcia","year":"2022","unstructured":"Matas-Garcia A, Milisenda JC, Espinosa G, et al. Gastrointestinal involvement in dermatomyositis. Diagnostics (Basel). 2022;12(5):1200.","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 4","key":"775_CR14","doi-asserted-by":"publisher","first-page":"iv18","DOI":"10.1093\/rheumatology\/kel311","volume":"45","author":"IE Lundberg","year":"2006","unstructured":"Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology. 2006;45(Suppl 4):iv18\u201321.","journal-title":"Rheumatology"},{"issue":"1","key":"775_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","volume":"83","author":"K Danko","year":"2004","unstructured":"Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine. 2004;83(1):35\u201342.","journal-title":"Medicine"},{"issue":"3","key":"775_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","volume":"14","author":"I Marie","year":"2012","unstructured":"Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275\u201385.","journal-title":"Curr Rheumatol Rep"},{"issue":"14","key":"775_CR17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022;387(14):1264\u201378.","journal-title":"N Engl J Med"},{"issue":"1","key":"775_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023677","volume":"100","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase\u00a0III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM Study\u201d). Medicine. 2021;100(1):e23677.","journal-title":"Medicine"},{"issue":"1","key":"775_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13075-023-03232-2","volume":"26","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024;26(1):27.","journal-title":"Arthritis Res Ther"},{"key":"775_CR20","unstructured":"Myositis disease activity assessment tool (MDAAT), 2005, version 2. https:\/\/www.niehs.nih.gov\/sites\/default\/files\/2025-05\/myositis_disease_activity_assessment_tool_2009_pdfat_508.pdf. Accessed Apr 2025."},{"issue":"8","key":"775_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"775_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"key":"775_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102234","volume":"64","author":"VP Werth","year":"2023","unstructured":"Werth VP, Aggarwal R, Charles-Schoeman C, et al. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. EClinicalMedicine. 2023;64:102234.","journal-title":"EClinicalMedicine"},{"key":"775_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/ITT.S381472","volume":"13","author":"L Cassard","year":"2024","unstructured":"Cassard L, Seraly N, Riegert M, Patel A, Fernandez AP. Dermatomyositis: practical guidance and unmet needs. Immunotargets Ther. 2024;13:151\u201372.","journal-title":"Immunotargets Ther"},{"key":"775_CR25","doi-asserted-by":"crossref","unstructured":"Charles-Schoeman C, Schessl J, Bata-Csorgo Z, et al. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. Rheumatology (Oxford). 2025;64(6):3767\u201376.","DOI":"10.1093\/rheumatology\/keaf070"},{"key":"775_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","volume":"154","author":"JA Huapaya","year":"2019","unstructured":"Huapaya JA, Hallowell R, Silhan L, et al. Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Respir Med. 2019;154:6\u201311.","journal-title":"Respir Med"},{"issue":"9","key":"775_CR27","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","volume":"61","author":"LM Wang","year":"2022","unstructured":"Wang LM, Yang QH, Zhang L, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology. 2022;61(9):3704\u201310.","journal-title":"Rheumatology"},{"issue":"7","key":"775_CR28","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/jcm9072150","volume":"9","author":"B Labeit","year":"2020","unstructured":"Labeit B, Pawlitzki M, Ruck T, et al. The impact of dysphagia in myositis: a systematic review and meta-analysis. J Clin Med. 2020;9(7):2150.","journal-title":"J Clin Med"},{"issue":"3","key":"775_CR29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/rheumatology\/keaa443","volume":"60","author":"M Giannini","year":"2020","unstructured":"Giannini M, Fiorella ML, Tampoia M, et al. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology. 2020;60(3):1234\u201342.","journal-title":"Rheumatology"},{"issue":"6","key":"775_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.amjmed.2014.02.002","volume":"127","author":"ME Tavel","year":"2014","unstructured":"Tavel ME. The placebo effect: the good, the bad, and the ugly. Am J Med. 2014;127(6):484\u20138.","journal-title":"Am J Med"}],"updated-by":[{"DOI":"10.1007\/s40744-026-00873-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00775-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:30Z","timestamp":1786685550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00775-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct a sentence starting \"With IVIg, the proportions of patients with arthritis...\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40744-026-00873-y","URL":"https:\/\/doi.org\/10.1007\/s40744-026-00873-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rohit Aggarwal has received research grants or contracts from Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Janssen, Mallinckrodt, Pfizer, and Q32 Bio; and has acted as a consultant for Alexion, ANI Pharmaceuticals, Argenx, Artasome, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cabaletta Bio, Capella Bioscience, Corbus, CSL Behring, EMD Serono, Galapagos, Horizon Therapeutics, I-Cell, Immunovant, Janssen, Kezar, Kyverna, Lilly, Novartis, Nuvig Therapeutics, Octapharma, Pfizer, Roivant, Sanofi, Teva, Tourmaline Bio, and Verismo Therapeutics. Joachim Schessl has received support for the current manuscript and funding and consultancy fees from Octapharma; and honoraria for presentations from Pfizer. Zsuzsanna Bata-Cs\u00f6rg\u0151 has received payment or honoraria for lectures from Sanofi, Berlin-Chemie and AbbVie; support for attending meetings from Sanofi and Biotest AG; and unpaid board membership in the Hungarian Dermatology and Immunology and Allergy Societies. Mazen M. Dimachkie has received grants from Alexion\/AstraZeneca, Alnylam Pharmaceuticals, Amicus, Argenx, Bristol Myers Squibb, Catalyst, CSL Behring, FDA\/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma\/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, and The Myositis Association; consultancy fees, payment, or honoraria for lectures, presentations, manuscript writing, or educational events, and participated on a Data Safety Monitoring Board or Advisory Board for Abata\/Third Rock, Abcuro, Amicus, Argenx, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance\/Labcorp, CSL Behring, Dianthus, Horizon, EMD Serono\/Merck, Fortrea, Ig Society, Inc., Ipsen, Janssen, Medlink, Nuvig Therapeutics, Octapharma, Priovant, Sanofi Genzyme, Shire Takeda, TACT\/Treat NMD, UCB Biopharma, and ValenzaBio; and received royalty fees or licenses, consultancy fees, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Wolters Kluwer Health\/UpToDate. Zoltan Griger has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from AbbVie, Lilly, Novartis, Roche; received support for attending meetings and\/or travel from Biotest, CSL Behring, Novartis, AbbVie, and Lilly; and participated on a Data Safety Monitoring Board or Advisory Board for Octapharma. Chester V. Oddis has received research support from Genentech and consulting fees from Pfizer. Elena Schiopu has received fees for consultancy and speaking bureaus from Johnson and Johnson and Novartis; and received research funds as institutional PI from SetPoint, Galapagos, Johnson and Johnson, BI, Lilly, Argenx, EMD Serrono, Priovant, Novartis, BMS, Zena Pharmaceuticals and Horizons\/Amgen. Jiri Vencovsk\u00fd has received support for the current manuscript from the Czech Ministry of Health; grants or contracts from AbbVie; consulting fees from Argenx, Eli Lilly, and ReBait; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Werfen and Octapharma; and participated on a Data Safety Monitoring Board or Advisory Board for Horizon, Kezar, Galapagos, Boehringer, and Octapharma. Elisabeth Clodi is an employee of Octapharma Pharmazeutika Produktionsges.m.b.H. Todd Levine is a consultant for FFF Enterprises. Christina Charles-Schoeman has received grants or contracts from Pfizer, Bristol Myers Squibb, AbbVie, CSL Behring, Alexion, and Priovant; consulting fees from Pfizer, Bristol Myers Squibb, AbbVie, Octapharma, Galapagos, Recludix, and Boehringer Ingelheim Pharmaceuticals. Sergey Moiseev has no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. ProDERM was approved by the relevant independent ethics committees or institutional review boards, as listed in the Ethics Committees section of the Supplementary Material. Each patient provided written, informed consent before being exposed to any study-related procedure, including screening tests for eligibility [\n                      \n                      ,\n                      \n                      ]. Specific consent for publication was not provided as all data in this international study (from 36 European and North American centers) is fully anonymized.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}